Pilz Stefan, Tomaschitz Andreas, Stepan Vinzenz, Obermayer-Pietsch Barbara, Fahrleitner-Pammer Astrid, Schweighofer Natascha, Portugaller Horst R, Sourij Harald, Dobnig Harald, Meinitzer Andreas, Pieber Thomas R
Department of Internal Medicine, Division of Endocrinology and Nuclear Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.
BMC Endocr Disord. 2009 Apr 7;9:11. doi: 10.1186/1472-6823-9-11.
Primary aldosteronism (PA) affects approximately 5 to 10% of all patients with arterial hypertension and is associated with an excess rate of cardiovascular complications that can be significantly reduced by a targeted treatment. There exists a general consensus that the aldosterone to renin ratio should be used as a screening tool but valid data about the accuracy of the aldosterone to renin ratio in screening for PA are sparse. In the Graz endocrine causes of hypertension (GECOH) study we aim to prospectively evaluate diagnostic procedures for PA.
In this single center, diagnostic accuracy study we will enrol 400 patients that are routinely referred to our tertiary care center for screening for endocrine hypertension. We will determine the aldosterone to active renin ratio (AARR) as a screening test. In addition, all study participants will have a second determination of the AARR and will undergo a saline infusion test (SIT) as a confirmatory test. PA will be diagnosed in patients with at least one AARR of >or= 5.7 ng/dL/ng/L (including an aldosterone concentration of >or= 9 ng/dL) who have an aldosterone level of >or= 10 ng/dL after the saline infusion test. As a primary outcome we will calculate the receiver operating characteristic curve of the AARR in diagnosing PA. Secondary outcomes include the test characteristics of the saline infusion test involving a comparison with 24 hours urine aldosterone levels and the accuracy of the aldosterone to renin activity ratio in diagnosing PA. In addition we will evaluate whether the use of beta-blockers significantly alters the accuracy of the AARR and we will validate our laboratory methods for aldosterone and renin.
Screening for PA with subsequent targeted treatment is of great potential benefit for hypertensive patients. In the GECOH study we will evaluate a standardised procedure for screening and diagnosing of this disease.
原发性醛固酮增多症(PA)影响约5%至10%的动脉高血压患者,并与心血管并发症的高发生率相关,而针对性治疗可显著降低该发生率。普遍共识是,醛固酮与肾素比值应作为一种筛查工具,但关于醛固酮与肾素比值在PA筛查中准确性的有效数据稀少。在格拉茨高血压内分泌病因(GECOH)研究中,我们旨在前瞻性评估PA的诊断程序。
在这项单中心诊断准确性研究中,我们将招募400名常规转诊至我们三级医疗中心进行内分泌高血压筛查的患者。我们将测定醛固酮与活性肾素比值(AARR)作为筛查试验。此外,所有研究参与者将再次测定AARR,并接受盐水输注试验(SIT)作为确诊试验。盐水输注试验后醛固酮水平≥10 ng/dL且至少有一次AARR≥5.7 ng/dL/ng/L(包括醛固酮浓度≥9 ng/dL)的患者将被诊断为PA。作为主要结局,我们将计算AARR诊断PA的受试者工作特征曲线。次要结局包括盐水输注试验的检测特征,涉及与24小时尿醛固酮水平的比较以及醛固酮与肾素活性比值诊断PA的准确性。此外,我们将评估β受体阻滞剂的使用是否会显著改变AARR的准确性,并验证我们实验室测定醛固酮和肾素的方法。
对PA进行筛查并随后进行针对性治疗对高血压患者具有巨大的潜在益处。在GECOH研究中,我们将评估这种疾病筛查和诊断的标准化程序。